Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHL907 MAD Study in Healthy Adults
NCT07580924Phase 1Recruiting
- Sponsor
- NeuHyll
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NHL907 (16 arms), sponsored by NeuHyll. Primary endpoint: Treatment Emergent Adverse Events. Started May 2026; status: recruiting.
02
Drugs
NHL907
Beyond the preview
Go deeper on NCT07580924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07580924.